Predictive factors of efficacy to pembrolizumab in advanced NSCLC patients with high PD-L1 expression.

被引：0

作者：

Piedra, A. ^{[1
]}

Barba Joaquin, A. ^{[1
]}

Mosquera Martinez, J. ^{[2
]}

Fernandez Bruno, M. ^{[2
]}

Cordeiro Gonzalez, P. ^{[3
]}

Sullivan, I. G. ^{[1
]}

Riudavets Melia, M. ^{[1
]}

Aguado Sorolla, M. ^{[1
]}

Gallardo Melo, P. ^{[1
]}

Martin Cullell, B. ^{[4
]}

Gavira, J. ^{[1
]}

Tapia, J. C. ^{[1
]}

Romano, A. ^{[1
]}

Bosma, F. ^{[5
]}

Sanchez Del Rio, S. ^{[1
]}

Sanz Beltran, J. ^{[1
]}

Molina Perez, M. A. ^{[6
]}

Serra Lopez, J. ^{[1
]}

Garcia Campelo, M. R. ^{[7
]}

Majem Tarruella, M. ^{[1
]}

机构：

[1] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain

[2] CHUAC Complexo Hosp Univ A Coruna, Med Oncol Serv Dept, La Coruna, Spain

[3] CHUAC Complexo Hosp Univ A Coruna, Oncol Dept, La Coruna, Spain

[4] Hosp Santa Creu & Sant Pau, Dept Oncol, Barcelona, Spain

[5] Hosp Santa Creu & Sant Pau, Oncol, Barcelona, Spain

[6] Hosp Santa Creu & Sant Pau, Oncol Med, Barcelona, Spain

[7] Inst Invest Biomed A Coruna INIBIC, Dept Med Oncol, La Coruna, Spain

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.1223

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1098P

引用

页码：S1053 / S1053

页数：1

共 50 条

[21] Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations
Chen, Justin A.
Riess, Jonathan W.
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (07)
[22] Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations
Justin A. Chen
Jonathan W. Riess
Current Treatment Options in Oncology, 2020, 21
[23] Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab
Sanchez-Gastaldo, Amparo
Munoz-Fuentes, Miguel A.
Molina-Pinelo, Sonia
Alonso-Garcia, Miriam
Boyero, Laura
Bernabe-Caro, Reyes
TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (06) : 2509 - +
[24] HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC
Funaishi, Kunihiko
Yamaguchi, Kakuhiro
Tanahashi, Hiroki
Kurose, Koji
Sakamoto, Shinjiro
Horimasu, Yasushi
Masuda, Takeshi
Nakashima, Taku
Iwamoto, Hiroshi
Hamada, Hironobu
Oga, Toru
Oka, Mikio
Hattori, Noboru
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2025, 95 (01)
[25] Pembrolizumab for ED SCLC: Efficacy and Relationship with PD-L1 Expression
Ott, Patrick A.
Elez, Elenea
Hiret, Sandrine
Kim, Dong-Wan
Moss, Rebecca A.
Winser, Tammy
Yuan, Shuai Sammy
Dolled-Filhart, Marisa
Cheng, Jonathan
Piperdi, Bilal
Mehnert, Janice M.
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S193 - S193
[26] The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors
Schakenraad, Alexandra
Hashemi, Sayed
Twisk, Jos
Houda, Ilias
Ulas, Ezgi
Daniels, Johannes M. A.
Veltman, Joris
Bahce, I.
LUNG CANCER, 2021, 162 : 36 - 41
[27] PD-L1 expression in NSCLC
Janzic, U.
Kern, I.
Janzic, A.
Cavka, L.
Cufer, T.
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S58 - S59
[28] Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis
Ma, K.
Guo, Y.
Wang, Y.
Wang, X.
Xu, Y.
Sun, C.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S584 - S584
[29] PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901)
Liu, S. -Y. M.
Deng, J. -Y.
Yan, H. -H.
Yang, M. -Y.
Xu, C. -R.
Zheng, M. -Y.
Gan, B.
Zhang, X. -C.
Tu, H. -Y.
Yang, J. -J.
Chen, H. -J.
Wang, B. -C.
Li, Y.
Zhou, Q.
Wu, Y. -L.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S38 - S39
[30] High PD-L1 expression is associated with treatment response to pembrolizumab in patients with advanced biliary tract cancer
Kim, G.
Ahn, S.
Hwang, J-H.
Lee, J-C.
Kim, J.
ANNALS OF ONCOLOGY, 2019, 30

← 1 2 3 4 5 →